Rights & Society
New medicines recommended for approval by EMA
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended five new medicines for approval at its April 2026 meeting. This includes Redemplo (plozasiran) for familial chylomicronaemia syndrome (FCS). These recommendations are a crucial step towards making new treatments available to patients across the EU. The EMA's rigorous evaluation ensures that new medicines meet high standards of safety, efficacy, and quality before they can be authorized for use.
EMA recommends five new medicines, expanding treatment options for EU patients.